Diabetes medicine effects on heart chamber changes
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests a type of diabetes medicine (an SGLT2 inhibitor) to see if it helps improve heart function in people with type 2 diabetes. It specifically looks at changes in the left atrium, a chamber of the heart, and may help protect your heart over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 75 years old.
- You have type 2 diabetes and your blood sugar is well controlled (A1C of 7% or lower).
- You are not currently taking an SGLT2 inhibitor (a type of diabetes pill).
- You have a regular heartbeat without atrial fibrillation (a type of irregular heartbeat).
- You have not had a heart attack, heart surgery, or a procedure to open blocked arteries.
- You do not have severe heart valve problems, kidney disease, or very high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether two types of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in people with type 2 diabetes. It involves a first group that reviews past medical records, and a second group that will be monitored for 6 months after starting an SGLT2 inhibitor to see how their heart function changes.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
Hear when a new SGLT 2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.